AlphAIAlphAI — Financial news for AI agents
yahoo.comSEP 163 min read$LLY

Eli Lilly Vs. Merck: One is a No-Brainer to Hold Through 2030

Eli Lilly (LLY) reported Q2 revenue of $23B, up 48% YoY, driven by Mounjaro and Zepbound. Merck (MRK) saw 5% growth, with KEYTRUDA nearing peak penetration. Lilly raised FY2026 guidance to $85-$87B and has an 86% gross margin. Merck's P/E is 15x, appealing to income investors. Lilly's pipeline includes retatrutide and Foundeo, while Merck focuses on new launches like Lipvendra.

Original reporting
yahoo.com
Published Sep 16, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 9:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Eli Lilly Vs. Merck: One is a No-Brainer to Hold Through 2030 — source image
Source · yahoo.com
Decision brief

The 30-second read

$LLYBullishHigh
01

Why it matters

Lilly's strong beat may drive buying pressure, while Merck's modest growth and acquisition charge could limit upside.

02

Market read

The earnings release provides fresh guidance for two major pharma stocks, influencing sector sentiment.

03

What to watch

Potential supply constraints for Lilly's incretin drugs and regulatory risks for Merck's KEYTRUDA pipeline.

Relevance 8/10Novelty 8/10Timing: post‑earnings release today

Background

The article compares Eli Lilly and Merck Q2 results, focusing on revenue growth, product performance, and guidance.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Eli Lilly reported Q2 revenue up 48% to $23B and raised FY2026 guidance to $85‑$87B.

Expected impact

Potential price rally on earnings beat and higher guidance.

Evidence & confidence

Revenue growth and guidance lift investor expectations.

$MRKNeutralMedium confidence
Context

Merck posted Q2 revenue of $16.6B (+5%) and noted a $5.7B acquisition charge, with guidance unchanged.

Expected impact

Possible modest downside or flat reaction.

Evidence & confidence

Growth slowdown and charge offset earnings momentum.

Market effects

Sector

Highlights divergent trajectories in the pharma/incretin vs. oncology space.

Regional

U.S. large‑cap pharma stocks may see re‑rating.

Global

Sets a benchmark for growth expectations in the global healthcare sector.

Counterpoint

What could challenge this read

Merck's lower valuation and dividend yield could attract value investors despite short‑term headwinds.

Key entities

  • company
    Eli Lilly

    Pharmaceutical company reporting strong Q2 results.

  • company
    Merck

    Pharmaceutical company reporting modest Q2 growth.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 17
$LLYMedAI 8/10

QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases

QurCan Therapeutics and Eli Lilly have entered a research and collaboration agreement to develop nucleic acid therapies for central and peripheral nervous system diseases. Lilly will invest strategically in QurCan, which could receive up to $237 million per program in milestones and royalties. QurCan will optimize therapeutics using its TERP platform, while Lilly will handle further research, clinical development, and commercialization.

antaranews.com2 min
SEP 16
$LLYHighAI 9/10

Eli Lilly Ramps Up Acquisitions to Diversify Beyond Weight-Loss Drug Dominance

Eli Lilly (LLY) seeks to diversify beyond its weight-loss drug dominance, with 65% of Q2 2026 revenue from Mounjaro, Zepbound, and Foundayo. The company is acquiring Merida Biosciences for up to $2.875B and partnering with QurCan Therapeutics to expand its pipeline. Recent acquisitions target mental health, sleep disorders, and infectious diseases, aiming to reduce long-term reliance on GLP-1 drugs.

nai500.com2 min
SEP 15
$LLYMed

Lilly’s Foundayo Quickly Gains Ground in the Oral Weight-Loss Market

Eli Lilly (LLY) reports its oral obesity drug Foundayo has captured over 30% of new U.S. patients starting oral weight-loss medicines, competing against Novo Nordisk's Wegovy. Foundayo, launched in April 2026, costs $149/month for self-pay patients. Lilly's incretin franchise, including Mounjaro and Zepbound, accounted for 65% of its revenue in H1 2026. The U.S. obesity-drug market is projected to exceed $100B annually by 2030, with oral treatments potentially making up over one-third of GLP-1 u

yahoo.com2 min
SEP 15
$LLYHigh

Mounjaro's maker has more room to run amid GLP-1 boom, Berenberg says

Berenberg upgraded Eli Lilly to buy, raising its price target to $1,400, citing strong performance in the obesity market and potential upside in its GLP-1 drug pipeline. Shares have risen 52% over the past year, and the analyst expects further growth. Eli Lilly makes Mounjaro and Zepbound, with additional drugs in development. 27 of 34 analysts recommend buying the stock. Shares gained over 1% in premarket trading.

cnbc.com2 min